Alkermes plc (ALKS) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - Specialty & Generic
Wait for pullback to $35.09. At $36.93 the A.R:R is 0.9:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $35.09 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Value-trap signals (2/5): Margin compression (op margin -0.2%), Material insider selling (9 sells, 0.02% of cap).
Alkermes is an Irish-headquartered biopharmaceutical company focused on neuroscience, with proprietary commercial products including VIVITROL (opioid/alcohol dependence), ARISTADA (schizophrenia), LYBALVI (schizophrenia/bipolar I), and LUMRYZ (narcolepsy, acquired via Avadel).... Read more
Wait for pullback to $35.09. At $36.93 the A.R:R is 0.9:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $35.09 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Value-trap signals (2/5): Margin compression (op margin -0.2%), Material insider selling (9 sells, 0.02% of cap). Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 6.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 69d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Alkermes plc
Latest news
- Universal Beteiligungs und Servicegesellschaft mbH Has $5.44 Million Stock Position in Alkermes plc $ALKS - MarketBeat — MarketBeat neutral
- Alkermes (NASDAQ:ALKS) Rating Increased to Hold at Zacks Research - MarketBeat — MarketBeat neutral
- ALKS stock surges 15% on Lilly-Centessa buyout igniting sleep pipeline hopes - MSN — MSN positive
- Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance — Yahoo Finance positive
- Alkermes stock hits 52-week high at $38.94 - Investing.com — Investing.com positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWcounterpartyJanssen9.0%10-K Item 1: 'Revenues from our collaborative arrangements with Janssen accounted for approximately 9% ... of our consolidated revenues for the years ended December 31, 2025'
Material Events(8-K, last 90d)
- 2026-02-25Item 5.02MEDIUMRichard F. Pops, CEO since Alkermes' founding, notified Board on February 24, 2026 of retirement effective July 31, 2026. Blair C. Jackson (current EVP and COO) appointed CEO effective August 1, 2026. Pops will serve as Senior Advisor through December 31, 2026 and remain as non-executive Chairman.SEC filing →
- 2026-02-12Item 1.01MEDIUMAlkermes entered into a $1.525B credit agreement on February 12, 2026 to fund the Avadel Acquisition: $750M Term Loan A (matures Feb 2031) and $775M Term Loan B (matures Aug 2031), both at Term SOFR + 2.75% per annum. JPMorgan Chase Bank serves as Administrative Agent.SEC filing →
- 2026-02-12Item 2.01MEDIUMAlkermes completed acquisition of Avadel Pharmaceuticals plc on February 12, 2026 for $21.00 per ordinary share in cash plus a $1.50 contingent value right. Adds LUMRYZ (sodium oxybate for narcolepsy) and Avadel's commercial organization to Alkermes' portfolio.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $35.09. At $36.93 the A.R:R is 0.9:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $35.09 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Value-trap signals (2/5): Margin compression (op margin -0.2%), Material insider selling (9 sells, 0.02% of cap). Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $40.89 (+10.7%), stop $32.40 (−14.0%), Setup A.R:R 2.1:1. Score 6.2/10, moderate confidence.
Take-profit target: $40.89 (+14.7% upside). Target $40.89 (+10.7%), stop $32.40 (−14.0%), Setup A.R:R 2.1:1. Stop-loss: $32.40.
Value-trap signals (2/5): Margin compression (op margin -0.2%), Material insider selling (9 sells, 0.02% of cap).
Alkermes plc trades at a P/E of 41.3 (forward 15.8). TrendMatrix value score: 6.1/10. Verdict: Buy (Wait for Entry).
24 analysts cover ALKS with a consensus score of 4.1/5. Average price target: $45.
What does Alkermes plc do?Alkermes is an Irish-headquartered biopharmaceutical company focused on neuroscience, with proprietary commercial...
Alkermes is an Irish-headquartered biopharmaceutical company focused on neuroscience, with proprietary commercial products including VIVITROL (opioid/alcohol dependence), ARISTADA (schizophrenia), LYBALVI (schizophrenia/bipolar I), and LUMRYZ (narcolepsy, acquired via Avadel). Revenue comes from product sales plus royalties from Janssen and Biogen; Janssen collaborative revenues declined to ~9% of total in 2025.